MIT Technology Review

Why “reprogramming” is the buzziest approach to reversing aging right now (opens in new tab)

Covers Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER‑100 for Optic NeuropathiesDiscussed on Hacker News

Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

Read the original article
Sign in to keep reading the full article.
Sign UpLog In

Keyboard Shortcuts

Navigation

Next / previous post
j/k
Open post
oorEnter
Preview post
v

Post Actions

Love post
a
Like post
l
Dislike post
d
Undo reaction
u
Save / unsave
s

Recommendations

Add interest / feed
Enter
Not interested
x

Go to

Home
gh
Interests
gi
Feeds
gf
Likes
gl
History
gy
Changelog
gc
Settings
gs
Discover
gb
Search
/

General

Show this help
?
Submit feedback
!
Close modal / unfocus
Esc

Press ? anytime to show this help